1155040-20-2

Upstream product

• 61341-26-2 3-methylthenoyl chloride 
• 87942-08-3 bromo(4-propylphenyl)magnesium 
• 181868-50-8 N-methoxy-N-methyl-3-methylthiophene-2-carboxamide 

Downstream Products

• 1344027-70-8 5-bromo-3-methyl-2-(4-propylbenzyl)thiophene 
• 1344027-71-9 5-iodo-3-methyl-2-(4-propylbenzyl)thiophene 
• 1344027-74-2 (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(4-methyl-5-(4-propylbenzyl)thiophen-2-yl)tetrahydro-2H-pyran-3,4,5-triol 
• 1344027-73-1 (3R,4S,5S,6R)-6-(hydroxymethyl)-2-methoxy-2-(4-methyl-5-(4-propylbenzyl)thiophen-2-yl)tetrahydro-2H-pyran-3,4,5-triol 
• 1344027-72-0 ((3R,4S,5R,6R)-2-(4-methyl-5-(4-propylbenzyl)thiophen-2-yl)-3,4,5-tris(trimethylsilyloxy)-6-((trimethylsilyloxy)methyl)tetrahydro-2H-pyran-2-ol) 

Relevant academic research and scientific papers

NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a novel compound with thiophene ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as

Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents

Novel thiophene C-aryl glucoside SGLT2 inhibitors were designed and synthesized. Two different types of thiophene derivatives were readily prepared. Among the compounds tested, ethylphenyl at the distal ring 71p showed the best in vitro inhibitory activit